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Abstract
Background: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were
demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U
at the physician’s discretion. Therefore, the objective of this prospective study was to compare the efficacy and
safety of OnabotulinumtoxinA 195 U vs. 155 U for the treatment of CM and medication overuse headache (MOH)
during a 2-year period.
Methods: We prospectively evaluated the mean reduction in headache days, migraine days, acute pain medication
intake days and Headache Impact Test (HIT)-6 score in 172 patients injected with OnabotulinumtoxinA
195 U. Successively, we compared the efficacy measures with data of 155 patients injected with OnabotulinumtoxinA
155 U and followed up for 2 years. All patients were affected by CM and MOH, and failed one or more previous
detoxification and preventative therapies.
Results: Both OnabotulinumtoxinA 195 U and 155 U reduced significantly the number of headache and migraine
days, acute pain medication intake days and HIT-6 score, when compared with the baseline measures. Nevertheless,
OnabotulinumtoxinA 195 U proved to be superior of 155 U in all efficacy measures since the first injection and for all
the 2 years of treatment, with the exception of the reduction in pain medication intake days that resulted significantly
larger with 195 U only after the 4th injection. The safety and tolerability of the two doses were similar and treatment
related adverse events were transient and mild-moderate.
Conclusions: This study represents the largest and longest post-marketing studies of doses comparison with
OnabotulinumtoxinA in a real-life clinical setting.
Here, we demonstrate the superior efficacy of OnabotulinumtoxinA 195 U compared to 155 U in CM patients with
MOH during a 2-year treatment period with similar safety and tolerability profile.
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Background
Migraine has a large individual and socioeconomic bur-
den of disease and, globally, is currently considered the
sixth most influential disabling condition according to
World Health Organization [1, 2].
Chronic migraine (CM) is a complex and debilitating
neurological disorder with a prevalence ranging 1–3 %
of the general population and an incidence estimated to
be 2.5 % per year [3].
Patients with CM are more likely to have a lower
health-related quality of life (HRQoL), greater lost pro-
ductive time, and greater healthcare resource utilization
than episodic migraine patients [4–6].
A significant proportion of patients with CM have a
high intake of abortive medications. It is estimated that
around 50–80 % of patients with CM referring to head-
ache clinics show analgesic overuse that may lead to the
development of medication overuse headache (MOH)
[7]. There is not a complete agreement whether MOH is
a consequence or a cause of CM [8].
In presence of MOH, prophylactic treatment will be
more effective after an adequate withdrawal from the
overused medication [9, 10]. At present, prophylactic
treatment options are limited and only around the 33 %
of CM patients report to be treated and take prophylac-
tic medications [11].
For decades, antiepileptic drugs (e.g., topiramate, dival-
proex sodium), antihypertensive agents (e.g., beta blockers,
calcium channel blockers, angiotensin-converting enzyme
[ACE] inhibitors, aldosterone receptor blockers) and tri-
cyclic antidepressants (e.g., amitriptyline, nortriptyline)
have been used “off-label” in CM prevention.
Nowadays, OnabotulinumtoxinA is the unique drug
specifically indicated for prophylaxis of headache in
adult patients with CM [12]. This indication is based on
the result of two large-scale, placebo-controlled, multi-
center trials (PREEMPT: Phase 3 REsearch Evaluating
Migraine Prophylaxis Therapy) that demonstrated the
efficacy, safety and tolerability of OnabotulinumtoxinA
(155–195 U) as a prophylactic treatment for CM in
adults [13–15].
The OnabotulinumtoxinA administration used in the
PREEMPT protocol required the intramuscular injection
of 155 U of OnabotulinumtoxinA in 31 sites across 7
head and neck muscles using a “fixed-site, fixed-dose”
(FSFD) injection paradigm (each injection was 5 U) [16].
Up to 40 U of additional OnabotulinumtoxinA could
have been injected at the physician’s discretion using a
“follow the pain” (FTP) strategy in 8 additional sites
across 3 head and neck muscles [16].
The mechanisms by which OnabotulinumtoxinA de-
creases the frequency and intensity of pain attacks in
CM patients have not been clearly clarified yet. It is
known that the activation of the trigeminovascular
system is accompanied by release of vasoactive neuro-
peptides from the presynaptic nerve terminals around
leptomeningeal and pericranial vessels [17]. The local re-
lease of these neuropeptides induces vasodilation and
neurogenic inflammation [17]. Repeated episodes of acti-
vation of the trigeminovascular system can sensitize cen-
tral pain pathways and lead to migraine chronicization
[18]. OnabotulinumtoxinA inhibits the release of neuro-
transmitters (such as serotonin, noradrenaline, dopamine,
Gamma-Amynobutirric Acid [GABA], acetylcholine, glu-
tamate, substance P, and Calcitonin Gene-Related Peptide
[CGRP]) from peripheral terminals of primary afferents
[19], thereby preventing the neurogenic inflammation.
Consequently, the peripheral sensitization of nociceptive
nerve fibers is inhibited and indirectly reduces the central
sensitization [20]. Moreover, it has been recently hypothe-
sized that the antinociceptive effect could not be only
dependent from a peripheral mechanism of action of the
toxin, but even centrally mediated and axonal transport-
dependent [21].
Our experience with OnabotulinumtoxinA for the pre-
vention of chronic daily headaches started in 2001 [22].
In our Headache Clinic the preventive treatment with
OnabotulinumtoxinA was offered to all the adults pa-
tients that were affected by CM with or without medica-
tion overuse (diagnosis made according with the IHS
criteria 2004 revised in 2006) (Headache Classification
Subcommittee; Headache Classification Committee)
[23, 24]. We offered such treatment only to patients with
contraindications or lack of efficacy or tolerability to other
preventive drugs (beta-blockers, calcium channel blockers,
antiepileptics and antidepressants). We did not offer Ona-
botulinumtoxinA treatment to patients with co-morbid
neuromuscular disorders, psychiatric diseases considered
incompatible with such kind of treatment, pregnancy and
breast-feeding.
Since 2010, we have strictly followed the injection
paradigm proposed in the PREEMPT studies [16] using
only the FSFD paradigm (155 U in 31 injection sites)
and, since 2012, we adopted as standard the combined
paradigm FSFD+ FTP (195 U in 39 injection sites) for all
the new patients treated with OnabotulinumtoxinA.
With the except of the PREEEMPT studies, large and
long-term studies on OnabotulinumtoxinA efficacy and
safety have not been published. Moreover, the PREEMPT
studies allowed the variable dose from 155 to 195 U, fol-
lowing the pain localization. In this prospective study, we
used the 195 U dose and we compared the efficacy and
safety profile for the treatment of CM and MOH with a
population treated with 155 U over a 2 years period.
Methods
The protocol was reviewed and approved by the Ethical
Committee of Sant’Andrea Hospital, Sapienza University
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of Rome. Each patient gave a free, informed consent for
the participation in the study and the analysis and publi-
cation of the protocol data.
We included in the study all the patients affected by
CM with MOH, able to fill diaries without any lack of
information, referred to our Headache Clinic between
January 2012 and January 2013 and followed up for two
years.
All patients overused acute pain medications during
the one-month baseline period. Medication overuse
was defined as simple analgesics intake on ≥15 days,
or other medication types or combination of types in-
take for ≥10 days, with intake ≥2 days/week from the
category of overuse.
We included only patients with criteria for MOH who
had failed one or more withdrawal attempt, and all the
CM patients who had received and failed other preventive
therapies due to lack of efficacy or intolerable side effects.
Any patient was allowed to take other preventive oral
medication during treatment with OnabotulinumtoxinA.
Patients were treated with OnabotulinumtoxinA injec-
tions, in multiple sites, combining the “FDFS” and the
“FTP” injection paradigm according to the protocol of
the PREEMPT study, at the dosage of 195 U for 39 sites.
Every session of local injection was repeated every
3 months (±1 week) during a 2-year period.
Headache days, migraine days, and acute pain medica-
tion intake were used as efficacy measures. Baseline data
were collected from patients headache diary referred to
the previous month before starting OnabotulinumtoxinA,
and patients were evaluated every three months at the
time of each injection. Every six months patients were
asked to fill the Headache Impact Test (HIT)-6, used as a
measure of efficacy as well, and the results were compared
with the baseline score. During the 24 months all adverse
events (AEs), related to the drug, were registered and used
as a safety measure.
To evaluate if the 195 U was associate with a different
efficacy and tolerability than the 155 U, we compared
our outcomes with those from a population of patients
treated with OnabotulinumtoxinA 155 U and followed
up for 2 years with the same injections and clinical
evaluation schedule [25].
Continuous variables are reported as mean ± standard
deviation, rates and categorical values are reported as
subjects-counts and percentage. In the population trea-
ted with OnabotulinumtoxinA 195 U, paired t-Test was
used to compare the mean headache days, migraine
days, medication intake days and HIT-6 score at baseline
and at each cycle of injections after Hartley’s ƒ-Max test
to assess equal variance of data. A χ2 test was used to
compare categorical variables.
The comparison between OnabotulinumtoxinA 155 U
and 195 U was performed using the Student’s t-Test for
the continuous variables and the χ2 test for the cate-
gorical variables. p ≤ 0.05 was considered statistically
significant.
Results
Demographic and baseline headache characteristics
The initial population included was of 172 patients but
only 143 patients completed the 2 years follow-up.
Table 1 shows the reasons for OnabotulinumtoxinA dis-
continuation before 24 months.
Demographic and baseline headache characteristics of
the 143 patients who completed the protocol are reported
in Table 2, together with the comparison with the same
demographic data of 132 patients treated with 155 U.
The majority of patients were female (79.7 %), with
mean age 44.9 years (range 18–78). The average time
since onset of CM was 9.3 years (range 1–40) (Table 2).
The 95.8 % of patients had a severe (≥60) HIT-6 score.
No statistically significant differences in demographic
and clinical characteristics at baseline were found be-
tween the 155 U and 195 U groups of patients (Table 2).
Efficacy of 195 U
The comparison of all pre- and post-treatment outcomes
is shown in Table 3. The headache days per month de-
creased significantly during the period of treatment from
the first to the eighth session of therapy (pre 22.2 ± 4.9,
post 4.1 ± 1.0; p < 0.001).
There was also a significant reduction of the migraine
days per month during the period of treatment from the
first to the eighth session of therapy (pre 21.6 ± 4.8, post
3.8 ± 1.0; p < 0.001).
Accordingly, also medication intake days decreased
significantly during the period of treatment from the
first to the eighth session of therapy (pre 21.0 ± 5.1, post
3.7 ± 1.3; p < 0.001).
The mean HIT-6 score decreased significantly during
the period of treatment from the first to the last injec-
tion (pre 67.9 ± 4.2, post 49 ± 6.7; p < 0.001), and the pro-
portion of patients with severe (≥60) HIT-6 score
decreased as well (pre 95.8 %, post 15.4 %) (Additional
file 1: Table S1). After two years of treatment the mean
HIT-6 score was ≤55 (some impact, little or no impact)
Table 1 Reasons for OnabotulinumtoxinA discontinuation prior
to 24 months
Discontinuations due to: n = 29 (16.9 %)
OnabotulinumtoxinA indepent AEs 7 (4.1 %)
Not effective 5 (2.9 %)
Pregnancy 4 (2.3 %)
Drop out 6 (3.5 %)
Personal reasons 7 (4.1 %)
AEs adverse events
Negro et al. The Journal of Headache and Pain  (2016) 17:1 Page 3 of 9
in 68.2 % of patients and ≤49 (little or no impact) in
40.9 % of patients (data not shown). Notably, all the effi-
cacy measures showed a progressive reduction over the
2 years of treatment, that resulted all significant when
compared with baseline measures.
Comparison between 195 U and 155 U
A graphic comparison of all pre- and post-treatment
outcomes in the two populations treated with
OnabotulinumtoxinA 195 U and 155 U are shown in
Figs. 1, 2, 3 and 4.
Although both dosages were per se effective in redu-
cing headache days frequency since the first injection,
OnabotulinumtoxinA 195 U was significantly more ef-
fective than the 155 U in reducing the mean headache
days at every time point (p < 0.001) (Fig. 1, Additional
file 1: Table S2).
There was also a significantly larger reduction of mi-
graine days in the group treated with 195 U (p < 0.001)
(Fig. 2, Additional file 1: Table S3). Moreover,
OnabotulinumtoxinA 195 U also significantly decreased
medication intake days per month, even if only after the
second injection (p < 0.001) (Fig. 3, Additional file 1:
Table S4).
Similar results were evident also when comparing the
mean HIT-6 score between the 195 U and the 155 U
treated groups. In fact, OnabotulinumtoxinA 195 U was
significantly more effective in reducing the mean HIT-6
score during all the treatment period (p < 0.05) (Fig. 4,
Additional file 1: Table S5), even if the proportion of
patients with severe (≥60) HIT-6 score was not sig-
nificantly different between the 195 U and the 155 U
groups, with the exception of the third injection time
(Additional file 1: Table S1).
Safety and tolerability
Treatment-related AEs were consistent with the known
tolerability profile of OnabotulinumtoxinA and were not
significantly different between the 195 U and the 155 U
treated patients (Table 4). In both groups, the AEs were
mild to moderate for severity and persisted for less than
a week (e.g., headache, injection-site pain) to a max-
imum of two months (e.g., eyelid ptosis, cervical muscu-
loskeletal weakness).
Table 2 Baseline demographics and clinical characteristics of the OnabotulinumtoxinA 155 U e 195 U treated groups
OnabotulinumtoxinA 155 U (n = 132) OnabotulinumtoxinA 195 U (n = 143) t/χ2 P value
Mean age, years 43.2 ± 13.5 (range 18–76 years) 44.9 ± 12.7 (range 18–78 years) 1.08 0.289
Female, % (n) 81.8 (108) 79.7 (114) 0.08 0.773
Diagnosis of chronic migraine, years 7.6 ± 4.3 (range 0.5–10) 8.4 ± 4.7 (range 1–12 years) 1.47 0.143
Years from the onset of chronic migraine 10.2 ± 4.8 (range 1–40) 9.3 ± 5.1 (range 1–40 years) 1.50 0.133
Monthly headache days 22.3 ± 4.1 22.2 ± 4.9 0.19 0.850
Monthly migraine days 21.4 ± 4.3 21.6 ± 4.8 0.34 0.734
Monthly pain medication intake days 20.8 ± 4.5 21 ± 5.1 0.31 0.757
Mean HIT-6 score 68.9 ± 4.3 67.9 ± 4.2 1.64 0.102
Patients with severe HIT-6, % (n) 93.9 (124) 95.8 (137) 0.18 0.668
Data are presented as mean ± standard deviation; HIT, Headache Impact Test; Scores of 36–49: little or no impact; 50–55: some impact; 56–59: substantial
impact; ≥60: severe impact
Table 3 Pre- and post-treatment outcomes in OnabotulinumtoxinA 195 U treated group
Headache days Migraine days Medication intake days HIT-6
Baseline (1st injection) 22.2 ± 4.9 21.6 ± 4.8 21.0 ± 5.1 67.9 ± 4.2
3 months (2nd injection) 14.1 ± 3.4* 13.5 ± 3.6* 13.8 ± 3.2* –
6 months (3rd injection) 10.2 ± 2.8* 9.7 ± 2.7* 9.9 ± 1.9* 61 ± 3.9*
9 months (4th injection) 7.4 ± 2.2* 6.9 ± 1.6* 7.0 ± 1.6* –
12 months (5th injection) 5.7 ± 1.7* 5.4 ± 1.2* 5.6 ± 1.4* 56.8 ± 3.8*
15 months (6th injection) 5.4 ± 1.2* 4.8 ± 1.0* 5.1 ± 1.3* –
18 months (7th injection) 4.9 ± 1.3* 4.5 ± 1.0* 4.7 ± 1.3* 54 ± 4.6*
21 months (8th injection) 4.4 ± 1.2* 4.1 ± 1.0* 4.2 ± 1.4* –
24 months 4.1 ± 1.0* 3.8 ± 1.0* 3.7 ± 1.3* 49 ± 6.7*
Data are presented as mean ± standard deviation
*p ≤ 0.05
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Fig. 1 Comparison of the mean change in frequency of headache days in the OnabotulinumtoxinA 155 U and 195 U treated groups. *p < 0.001
Fig. 2 Comparison of the mean change in frequency of migraine days in the OnabotulinumtoxinA 155 U and 195 U treated groups. *p < 0.001
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Fig. 3 Comparison of the mean change in pain medication intake days in the OnabotulinumtoxinA 155 U and 195 U treated groups. *p < 0.001
Fig. 4 Comparison of the mean change in HIT-6 score in the OnabotulinumtoxinA 155 U and 195 U treated groups. *p≤ 0.002. **p < 0.05
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Some AEs occurred more frequently during the first
three cycles of injections for both groups (>75 % of all
the cases of neck pain and musculoskeletal weakness),
whereas others AEs did not show any correlation with
the treatment cycle (e.g., headache, eyelid ptosis and
injection-site pain) (data not shown).
Discussion
CM is a serious clinical condition with high risk of
medication overuse given by the frequent partial re-
sponse to treatment, both abortive and preventive.
Therefore, the opportunity to provide new effective
therapeutic options to patients represents a crucial step
in CM treatment [26].
The PREEMPT clinical trials showed that Onabotuli-
numtoxinA is a safe, well-tolerated, and effective prophy-
lactic therapy for CM patients [13, 14]. To date, the
PREEMPT clinical program is the largest (1384 patients)
and longest (24-week, double-blind period followed by a
32-week, open-label phase) study in CM [15].
Its remarkable results led to the worldwide specific
indication of OnabotulinumtoxinA for the prevention of
headache in CM patients [16].
One of the criticisms made to the PREEMPT study de-
sign regarded the high percentage (nearly 40 %) of the
CM recruited patients that have never received other
drugs for migraine prophylaxis. Therefore, in this study
we recruited only CM patients that already failed other
preventive treatments that were subsequently treated
with OnabotulinumtoxinA for 24 months, without
taking any other prophylactic treatment.
Several studies have demonstrated that repeated injec-
tions over time are able to increase the benefit obtained
after the first cycle of treatment, with a prophylactic cu-
mulative effect [27, 28]. In this study, we demonstrated
the efficacy and safety of OnabotulinumtoxinA 195 U in
the CM with MOH treatment, over a period of
24 months.
Moreover, even if 195 U and the 155 U doses were
both effective and safe in the treatment of CM with
MOH [25], we found the higher dose being significantly
more effective then the 155 U in terms of mean reduc-
tion of headache days, migraine days, pain medication
intake days and HIT-6 score. Only the severe HIT-6
score proportion of patients did not significantly differ
between OnabotulinumtoxinA 195 U and 155 U over
the 24 months, with the exception of the second injec-
tion time (6 months) in which the 195 U proportion of
HIT-6 severe patients resulted significantly lower. These
results suggest that the OnabotulinumtoxinA higher
dose treatment lead to a faster reduction of the HIT-6
score. The 195 U superior efficacy in all the considered
measures was evident since the first injection and was
maintained over a period of two years, with the excep-
tion of the mean medication intake days reduction that
was larger with 195 U only after 6 months.
CM prevention and reduction of attacks might also be
essential for the cardiovascular risk reduction, as CM
represents an independent risk factor for cardiovascular
disorders and ischemic stroke [29]. The reduced attacks
frequency implies a greater intake of non-steroidal anti-
inflammatory drugs (NSAIDs) and triptans, both
associated with a greater likelihood of developing cardio-
vascular events [29]. Therefore, the greater efficacy of
195 U with respect to 155 U in reducing migraine, head-
ache and medication intake days might be also associ-
ated with a larger reduction of cardiovascular risk.
Migraine patients often suffer greatly as a result of the
systemic AEs related to the prophylactic drugs, reporting
a reduced attention, somnolence, tremor, dizziness, fa-
tigue, depression, loss of appetite, weight gain, hair loss
and changes in libido. These side effects are not known
in association with OnabotulinumtoxinA.
The safety and tolerability of OnabotulinumtoxinA
195 U were similar to that of OnabotulinumtoxinA 155
U. In our study we enrolled only CM with coexisting
MOH patients. We strongly believe that MOH might be
a consequence of CM and not just a simple and distinct
form of secondary headache [30].
One of the major criticisms made to the PREEMPT
studies was about the diagnosis of CM. In fact, in
PREEMPT studies, the 65.3 % of patients had medication
overuse, which, according to the ICHD-II, precluded the
diagnosis of CM [24]. In PREEMPT studies the decision
to not to exclude patients overusing acute medications
was based on a consultation with the Task Force of the
International Headache Society Clinical Trials Sub-
committee [31]. In fact, the Task Force guidelines for
controlled trials of CM prophylactic treatment in
adults recommended the inclusion and stratification
Table 4 Summary of the overall treatment-related AEs reported in
24 months in the OnabotulinumtoxinA 155 U and 195 U groups
OnabotulinumtoxinA
155 U (n= 132)
OnabotulinumtoxinA
195 U (n= 143)
χ2 P value
n (%) n (%)
Total
treatment-
related AEs
23 (17.5) 29 (20.3) 0.12 0.728
Injection-site
pain
4 (3.3) 5 (3.5) 0.01 0.911
Neck pain 5 (3.8) 6 (4.2) 0.03 0.868
Musculoskeletal
weakness
5 (3.8) 7 (4.9) 0.02 0.893
Eyelid ptosis 4 (2.9) 4 (2.8) 0.01 0.911
Headache 5 (3.7) 7 (4.9) 0.02 0.892
AEs adverse events
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of medications overusing patients in clinical studies
[32]. Accordingly, a sub-group analysis of the PREEMPT
data showed OnabotulinumtoxinA to be equally ef-
fective in patients affected by CM with medication
overuse [33]. In this study, we provided further evi-
dence in clinical setting of the OnabotulinumtoxinA
efficacy for the headache prophylaxis in CM with
MOH patients.
Several studies suggest that some migraineurs respond
better to OnabotulinumtoxinA than others. A better re-
sponse has been seen in: CM patients with unilateral
headache, pericranial allodynia and pericranial muscle
tenderness [34, 35]; those with imploding headache and
ocular headache [36]; those with a shorter disease dur-
ation (<30 years) [37]; and those with elevated interictal
plasma levels of CGRP and vasoactive intestinal peptide
(VIP) [38]. Conversely, the prevalence of aura, photo-
phobia, phonophobia, osmophobia, nausea, and throb-
bing are similar between responders and non-responders
[36]. Similarly the presence of white matter lesions at
MRI scans did not show the ability to predict a positive
response to OnabotulinumtoxinA [39]. In this study, we
did not evaluated inter-individual variations in headache
features, that might be predictive of a OnabotulinumtoxinA
better response, but we can state that the MOH
presence do not affect OnabotulinumtoxinA efficacy
in CM prophylaxis.
The pharmacologic profile of OnabotulinumtoxinA
makes it an appealing candidate for CM patients. Its long
duration of action (3 months on average) is attractive for
patients with poor compliance to the daily use of prevent-
ive medications [40], while its good safety profile makes it
the best option when other preventive medications are
poor tolerated or non-effective.
OnabotulinumtoxinA mechanism of action is poorly
understood. Recent studies have shown that Onabotuli-
numtoxinA is able to modulate the inflammatory media-
tors in the trigeminal ganglion [41] and decrease
interictal CGRP plasma levels in patients with CM [42],
and therefore be effective in the migraine attacks
prevention.
There are still questions open in the Onabotulinum-
toxinA treatment for CM, such as the possible existence
of response predictors (biomarkers, clinical features), the
possible OnabotulinumtoxinA paradigm variations de-
pending on the extent of the response, the possible
superior efficacy of concomitant oral prophylactic ther-
apies and the optimal management of patients after
2 years of treatment.
Conclusions
We believe that these results represent the largest and
longest post-marketing study of doses comparison with
OnabotulinumtoxinA in a real-life clinical setting.
OnabotulinumtoxinA administered at 195 U proved to
have indisputable advantages over the 155 U: higher effi-
cacy and same safety and tolerability profile maintained
even after a long period of treatment.
On the basis of our results we suggest that the preven-
tion of headache in CM with MOH should be obtained
with the higher OnabotulinumtoxinA dosage.
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